Please login to the form below

Not currently logged in


This page shows the latest MEDI8897 news and features for those working in and with pharma, biotech and healthcare.

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Sanofi is already active in this category after licensing rights to AstraZeneca’s phase II candidate MEDI8897 last year, with both projects aimed at providing treatment for already-established RSV infections.

Latest news

  • Regeneron drops RSV drug Regeneron drops RSV drug

    The failure of suptavumab to hit the mark in the NURSERY study removes a potential rival for AstraZeneca's RSV candidate MEDI8897 - recently partnered with Sanofi - which is currently in phase

  • Sanofi buys into AZ drug for preventing RSV infections Sanofi buys into AZ drug for preventing RSV infections

    The deal also includes up to 495m in development and sales milestone payments and focuses on MEDI8897, a follow-up to AZ's already-marketed Synagis (palivizumab) which is the first ... MEDI8897 is a fully-human antibody that has an extended half-life in

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase IIb.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...